Google
PMCB Stock Analysis — PHARMACYTE BIOTECH INC (Healthcare >> Biotechnology)
PMCB FAQ
What is PMCB's P/E ratio?
PHARMACYTE BIOTECH INC (PMCB) currently trades at a P/E ratio of 119.93.
What is PMCB's ROE?
PHARMACYTE BIOTECH INC reports a Return on Equity (ROE) of -1,376.50%.
What is PMCB's dividend yield?
PHARMACYTE BIOTECH INC offers a dividend yield of 0.00%.
What is PMCB's Quality Score?
Our AI rates PMCB's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PMCB?
Our AI Timing Score for PMCB is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PMCB belong to?
PHARMACYTE BIOTECH INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
PMCB AI Analysis Summary
Our AI summary for PMCB: PHARMACYTE BIOTECH INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 119.93, ROE of -1,376.50%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.58
Price
-0.02
(-4.00%)
Day Change
|
|
|---|
PMCB, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
1494
|
| Magic Formula Rank by ROE |
1494
|
| Magic Formula Rank by ROIC |
1632
|
| Price | 0.58 |
| PBV / Sector |
N/A / 5.20
|
| Earning Per Share | -1,000,000.00 |
| PE / Sector |
119.93 / 19.97
|
| PEG or PE/Growth / Sector |
0.02 / 1.22
GREAT
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.13 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:20 |
| Symbol | PMCB |
| Name | PHARMACYTE BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 10.74 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,498.75 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
Phone: 917 595 2850
Website: https://pharmacyte.com
Sector: Healthcare >> Biotechnology
Description: PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap